Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
出版年份 2021 全文链接
标题
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
作者
关键词
-
出版物
Frontiers in Neuroscience
Volume 15, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-09-04
DOI
10.3389/fnins.2021.733857
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Aducanumab and the FDA — where are we now?
- (2021) Howard Fillit et al. Nature Reviews Neurology
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Aducanumab for Alzheimer Disease
- (2021) G. Caleb Alexander et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
- (2021) Jeffrey Cummings et al. Alzheimers Research & Therapy
- Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
- (2020) Dieter Volc et al. LANCET NEUROLOGY
- Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
- (2020) Steven S. Plotkin et al. NEUROBIOLOGY OF DISEASE
- Invite Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials
- (2020) D. Boche et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
- (2020) Wassilios G. Meissner et al. MOVEMENT DISORDERS
- Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
- (2020) Jacqui T. Nimmo et al. Alzheimers Research & Therapy
- Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?
- (2019) Francesco Panza et al. ANNALS OF NEUROLOGY
- A walk through tau therapeutic strategies
- (2019) Santosh Jadhav et al. Acta Neuropathologica Communications
- Immunotherapy with ponezumab for probable cerebral amyloid angiopathy
- (2019) Claire Leurent et al. Annals of Clinical and Translational Neurology
- Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review
- (2019) Marie-Aleth Lacaille-Dubois PHYTOMEDICINE
- Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease
- (2019) James A R Nicoll et al. BRAIN
- Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
- (2019) Darren J. Schofield et al. NEUROBIOLOGY OF DISEASE
- ABBY
- (2018) Jeffrey L. Cummings et al. NEUROLOGY
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
- (2018) Stina Syvänen et al. Alzheimers Research & Therapy
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
- (2018) Joseph Jankovic et al. JAMA Neurology
- 39-Week Toxicity and Toxicokinetic Study of Ponezumab (PF-04360365) in Cynomolgus Monkeys with 12-Week Recovery Period
- (2018) Gary B. Freeman et al. JOURNAL OF ALZHEIMERS DISEASE
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
- (2018) Kristina Magnusson et al. JOURNAL OF ALZHEIMERS DISEASE
- Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
- (2018) Stephen Salloway et al. Alzheimers Research & Therapy
- SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
- (2018) Laurent Pradier et al. Alzheimers Research & Therapy
- Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
- (2018) Andreas Weihofen et al. NEUROBIOLOGY OF DISEASE
- Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies
- (2017) Jun Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
- (2016) Michael C. Irizarry et al. Alzheimers & Dementia
- Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
- (2016) Eric R. Siemers et al. Alzheimers & Dementia
- Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy
- (2016) Jing Liu et al. DRUGS & AGING
- Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
- (2016) Francesco Panza et al. Immunotherapy
- Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease
- (2016) Florence Pasquier et al. JOURNAL OF ALZHEIMERS DISEASE
- A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies
- (2016) Dante J. Marciani JOURNAL OF NEUROCHEMISTRY
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
- (2016) Adrian Ivanoiu et al. Alzheimers Research & Therapy
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
- (2016) Rik Vandenberghe et al. Alzheimers Research & Therapy
- In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy
- (2016) Mathieu D. Santin et al. Frontiers in Aging Neuroscience
- Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
- (2016) Mark Ultsch et al. Scientific Reports
- Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models
- (2015) Yvonne Bouter et al. ACTA NEUROPATHOLOGICA
- Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
- (2015) James P. Fuller et al. ACTA NEUROPATHOLOGICA
- Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity
- (2015) Kelly R. Bales et al. BRAIN
- Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
- (2015) Heii Arai et al. Current Alzheimer Research
- Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice
- (2015) Alexandra J. Mably et al. NEUROBIOLOGY OF DISEASE
- Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β
- (2015) Jay Amin et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
- (2015) Elvira Valera et al. Neurotherapeutics
- Tailoring the Antibody Response to Aggregated Aß Using Novel Alzheimer-Vaccines
- (2015) Markus Mandler et al. PLoS One
- Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
- (2015) Martin R Farlow et al. Alzheimers Research & Therapy
- Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
- (2014) D. Games et al. JOURNAL OF NEUROSCIENCE
- Combined Treatment with a BACE Inhibitor and Anti-A Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice
- (2014) H. Jacobsen et al. JOURNAL OF NEUROSCIENCE
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Active immunotherapy options for Alzheimer’s disease
- (2014) Bengt Winblad et al. Alzheimers Research & Therapy
- Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities
- (2013) Wagner Zago et al. Alzheimers & Dementia
- Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
- (2013) Elina Zotova et al. BRAIN
- Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease
- (2013) Aaron H. Burstein et al. CLINICAL NEUROPHARMACOLOGY
- Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease
- (2013) Jaren W. Landen et al. CLINICAL NEUROPHARMACOLOGY
- Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study
- (2013) Izuru Miyoshi et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Mechanisms of Action of Adjuvants
- (2013) Sunita Awate et al. Frontiers in Immunology
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice
- (2012) Gary B. Freeman et al. Current Alzheimer Research
- Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
- (2012) Frédérique Bard et al. EXPERIMENTAL NEUROLOGY
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
- (2012) O. Adolfsson et al. JOURNAL OF NEUROSCIENCE
- Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
- (2012) Reisa Sperling et al. LANCET NEUROLOGY
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
- (2012) Ronald B. DeMattos et al. NEURON
- The Aβ peptide conjugate vaccine, acc-001, generates n-terminal anti- Aβ antibodies in the absence of Aβ directed t-cell responses
- (2011) Michael Hagen et al. Alzheimers & Dementia
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
- (2011) Susanne Ostrowitzki ARCHIVES OF NEUROLOGY
- Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease
- (2011) Kazunori Uenaka et al. CLINICAL NEUROPHARMACOLOGY
- CpG DNA as a vaccine adjuvant
- (2011) Christian Bode et al. Expert Review of Vaccines
- AFFITOME® technology in neurodegenerative diseases: The doubling advantage
- (2011) Achim Schneeberger et al. Human vaccines & immunotherapeutics
- Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease
- (2011) Sherry L. La Porte et al. JOURNAL OF MOLECULAR BIOLOGY
- The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
- (2011) C. Wiessner et al. JOURNAL OF NEUROSCIENCE
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
- (2011) Eliezer Masliah et al. PLoS One
- Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
- (2010) Eric R. Siemers et al. CLINICAL NEUROPHARMACOLOGY
- Microglial alterations in human Alzheimer's disease following Aβ42 immunization
- (2010) E. Zotova et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection
- (2009) Karen Smith Korsholm et al. IMMUNOLOGY
- Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing
- (2009) A. Schneeberger et al. Journal of Nutrition Health & Aging
- An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
- (2009) Anna Lord et al. NEUROBIOLOGY OF DISEASE
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores
- (2008) Sid E. O’Bryant ARCHIVES OF NEUROLOGY
- Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain
- (2008) D. Boche et al. BRAIN
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Peripheral A subspecies as risk biomarkers of Alzheimer's disease
- (2008) N. Schupf et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search